The effect of methotrexate and azathioprine on the serum levels of IgA-alpha 1-antitrypsin complex in juvenile chronic arthritis
- PMID: 9292114
- DOI: 10.1590/s0100-879x1997000600010
The effect of methotrexate and azathioprine on the serum levels of IgA-alpha 1-antitrypsin complex in juvenile chronic arthritis
Abstract
In the present study we investigated the influence of methotrexate (MTX) and azathioprine (AZA) on the serum levels of the IgA-alpha 1-antitrypsin (IgA-AT) complex in patients with the systemic form of juvenile chronic arthritis (JCA). Fifty-six JCA patients (22 treated with MTX, 18 treated with AZA, and 16 not treated with any immunosuppressive agent) were enrolled in the study. MTX dosage ranged from 0.3 to 0.5 mg/kg-1 week-1, while AZA was given daily at an average dose of 1 mg/kg. MTX was given for 13 months (SD = 7 months) whereas AZA for 11 months (SD = 6 months). The average value of the complex was higher in JCA patients than in both control groups (0.74 +/- 0.73 U vs 0.37 +/- 0.13 U (control children), P < 0.001 and vs 0.23 +/- 0.12 U (control adults), P < 0.001). Values exceeding the normal range were found in twenty-two JCA patients (39.4%). Serum IgA-AT level was lowest in the MTX group compared to AZA and non-treated patients (0.56 +/- 0.24 U, 0.76 = 0.43 U, 0.95 +/- 0.52 U, respectively, P < 0.05). IgA values exceeding normal levels for age were found in 14% of the patients. A correlation between the levels of the IgA-AT complex and C-reactive protein (r = 0.43, P < 0.01), alpha 1-acid-glycoprotein (r = 0.45, P < 0.01), alpha 1-antichymotrypsin (r = 0.52, P < 0.01), alpha 1-antitrypsin (r = 0.40, P < 0.01) and IgA (r = 0.56, P < 0.01) was established.
Similar articles
-
Immunoglobulin levels in methotrexate treated paediatric rheumatology patients.Arch Dis Child. 2002 Aug;87(2):147-8. doi: 10.1136/adc.87.2.147. Arch Dis Child. 2002. PMID: 12138068 Free PMC article.
-
Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.Pharmacotherapy. 2017 Jun;37(6):700-711. doi: 10.1002/phar.1938. Pharmacotherapy. 2017. PMID: 28475276
-
Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis.Scand J Rheumatol. 2000;29(3):187-9. doi: 10.1080/030097400750002085. Scand J Rheumatol. 2000. PMID: 10898073 Clinical Trial.
-
Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.Eur J Paediatr Neurol. 2019 Jan;23(1):7-18. doi: 10.1016/j.ejpn.2018.09.008. Epub 2018 Sep 27. Eur J Paediatr Neurol. 2019. PMID: 30318435
-
On beyond methotrexate treatment of severe juvenile rheumatoid arthritis.Clin Exp Rheumatol. 1999 Jul-Aug;17(4):499-504. Clin Exp Rheumatol. 1999. PMID: 10464566 Review. No abstract available.
Cited by
-
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Clin Exp Immunol. 2016 Nov;186(2):115-133. doi: 10.1111/cei.12823. Epub 2016 Sep 8. Clin Exp Immunol. 2016. PMID: 27283488 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous